This installment of Supplier Spotlight® is on QPS – a global leader in clinical and preclinical research.
What is your company’s mission?
QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. The QPS logo includes a hummingbird, which represents our commitment to providing agility, flexibility and speed to our customer experience.
What products and services do you offer?
QPS has extensive experience in delivering a comprehensive list of services, including neuropharmacology, toxicology, DMPK, bioanalysis, translational medicine, cell & gene therapy, early and late phase clinical trials, study subject recruitment and other contract research support services. QPS offers these and other services across a broad range of therapeutic areas, including neurodegenerative disorders (Alzheimer, Parkinson, ALS), psychiatric diseases (schizophrenia, autism spectrum disorders), rare diseases (Gaucher, Niemann-Pick, Alport), cardiovascular, dermatology, endocrinology, oncology, vaccines and more.
In the area of neuropharmacology preclinical services, we offer efficacy studies and PK/PD studies in transgenic and non transgenic mouse/rat models, as well as in induced disease models. QPS also provides various in vitro screening assays in primary cells and immortalized cell lines.
What problems does your organization solve?
QPS has CLIA-certified and GLP-compliant laboratories ready to fast-track your novel coronavirus and COVID-19 RT-qPCR/QPCR and Serological Assays and vaccine development programs. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach, client satisfaction and turnkey laboratories and facilities.
What are the most innovative tools and technologies that you offer?
Over the last 25 years, the QPS neuropharmacology division has expanded its services for neurodegenerative diseases by including in vitro and in vivo drug development models of rare diseases into our extensive portfolio. In addition to in vivo treatment, surgery and behavioral tests, QPS also specializes in ex vivo biochemical and histological analyses of tissue through a plethora of methods. Due to such a wide range of services, QPS neuropharmacology is able to perform drug development analyses from cell free assays, in vitro and in vivo studies and clinical analyses of new NBEs/NCEs.
In addition, we are experts at method development supporting a wide range of new assay development. Most recently, QPS has developed assays to support detection, treatment and prevention of novel coronavirus.
What are your competitive advantages?
QPS has custom-built research solutions, a flexible approach to study design and a relentless focus on the customer. The core attributes of agility, flexibility and speed set QPS apart from the rest of the CRO world. We carefully listen to our customers’ specific needs and custom-build solutions designed solely with their success in mind.
Who are your clients?
QPS is a full service, global CRO working in close collaboration with a large international network of scientists, investigators and professionals. Our clients include small biotech start-ups and medium-sized biotech companies, as well as Top-50 pharmaceutical companies. We are glad to support as many researchers as possible in their mission to find urgently needed medical therapies, independent of size and type of company.
What new products and services are you developing in 2020?
QPS has always been known for GLP-compliant laboratories, and we have recently added CLIA-certified laboratories that are ready to fast-track your novel coronavirus (RT-qPCR/QPCR) and COVID-19 (Serological) assays, as well as novel coronavirus vaccine development and other cell & gene therapy programs.
The QPS neuropharmacology division has recently acquired two new mouse strains: zQ175 mice for Huntington`s disease and A53T-α-Synuclein mutated mice for Parkinson’s disease. Additionally, we have developed an in vitro seeding and lesion model by treating cells with A53T fibrillar human α-Synuclein.
Where are your laboratories and offices located?
QPS has 11 global locations, strategically placed across three continents. For more information about each location and the services available at that location, please visit www.qps.com/locations.
How has Scientist.com helped your business?
Our partnership with Scientist.com has helped QPS in several ways. Our presence on the platform allows us to reach a broad range of companies and potential clients, the majority of whom are likely to be interested in at least one of our many service lines. In addition, we can be highly targeted and specific with the information we provide, because the platform is laser focused on the scientific aspects of each project. We look forward to continuing our partnership.